Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Poly-L-lactic Acid for Skin Quality

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02003833
Recruitment Status : Completed
First Posted : December 6, 2013
Last Update Posted : November 20, 2015
Sponsor:
Information provided by (Responsible Party):
Neil Sadick, Sadick Research Group

Brief Summary:

Anecdotal evidence suggests that patients' skin quality may improve as a result of poly-L-lactic acid injection. While this is not the primary goal of such treatments it is often seen and described as so called "Sculptra glow".

The aim of this study is to evaluate the effect of repeated subcutaneous injections of poly-L-lactic acid (Sculptra Aesthetic) on skin quality.

Participating subjects will be part of the study for about 15 months. There will be an initial treatment period of up to 12 weeks, followed by a 12-month follow-up period. There will be a total of 7 scheduled visits.

This study is a double-blind, randomized study. "Double-blind" means that neither the subjects nor the study doctor will know who is receiving Sculptra Aesthetic or placebo. "Randomized" means that the group subjects will be placed in is decided by chance, similar to drawing numbers out of a hat or flipping a coin. Subjects will have a 1 out of 2 chance of receiving the active study drug. After the completion of the study, if subjects are assigned to the control (placebo) group they will receive free injections with Sculptra Aesthetic same as the treatment group.


Condition or disease Intervention/treatment Phase
Skin Aging Device: Poly-L-lactic acid Device: Placebo comparator Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Controlled, Multi-Centered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Improving Facial Wrinkles and Skin Quality
Study Start Date : September 2013
Actual Primary Completion Date : March 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Poly-L-lactic acid
Subjects in the treatment arm will receive three injections of 5 cc of poly-L-lactic acid (PLLA) into both sides of the face.
Device: Poly-L-lactic acid
Sculptra injections
Other Names:
  • Sculptra Aesthetic
  • P030050/S002

Placebo Comparator: Placebo
Subjects in the placebo arm will receive three injections of 5 cc of saline into both sides of the face. After the completion of the study, subjects in the placebo arm will receive free injections with Sculptra Aesthetic same as the treatment arm.
Device: Placebo comparator
saline injections
Other Name: Placebo




Primary Outcome Measures :
  1. Improvement in skin quality [ Time Frame: 15 months ]
    The primary endpoint is defined as the degree of improvement in skin quality measured by a blinded, trained evaluator using standardized pictures as well as live evaluations rated by a blinded investigator and the subjects


Secondary Outcome Measures :
  1. Improvement of skin physiology [ Time Frame: 15 months ]
    Non-invasive biophysical measurements will be used to assess sub-clinical changes in skin quality including skin hydration, elasticity, density and dermal thickness and a decrease in transepidermal water loss

  2. Investigator and patient satisfaction [ Time Frame: 15 months ]
    Investigator and patient satisfaction will be assessed with a quartile scale.

  3. Safety of repeated injections with Sculptra Aesthetic [ Time Frame: 15 months ]
    Safety analyses will be done on all treated patients, defined by any subject who received at least one study treatment. Compiled side effects, including all expected or unexpected side effects but not limited to site discomfort, redness, bruising, bleeding, itching, and swelling, small and larger lumps under the skin



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained including HIPAA authorization
  • Healthy females between 30 and 60 years of age
  • Subjects with Fitzpatrick photo skin types I-IV
  • Subjects with shallow to deep nasolabial fold contour deficiencies or other facial wrinkles
  • Subjects who agree not to have any procedures affecting facial wrinkles (e.g. filler, botulinum toxin, radiofrequency, laser, IPL, ultrasound) for the duration of the study
  • Subjects who do agree not to have any other procedures affecting skin quality (microdermabrasion, peels, acne treatments, etc.) for the duration of the study
  • Subjects who understand this study and are able to follow study instructions and are willing to attend the required study visits
  • Subjects who agree to be photographed for research reasons and their identity may not be concealed in these photographs.

Exclusion Criteria:

  • Subjects who are pregnant, planning to become pregnant or breastfeeding. A urine pregnancy test will be done to rule out pregnancy
  • Subjects of child-bearing potential who are not using an approved method of birth control (oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence). Females of non-childbearing potential are defined as post-menopausal (absence of menstrual bleeding for one year), hysterectomy or bilateral oophorectomy.
  • Subjects who cannot understand or are not willing to comply with the requirements of the study
  • Subjects who have a known allergy to poly-L-lactic acid, carboxymethylcellulose, non-pyrogenic mannitol or any anesthetic
  • Subjects who have taken any NSAIDs (aspirin, ibuprofen, etc.) within 7 days before treatment
  • Subjects who have taken acetaminophen 24 hours before treatment
  • Subjects who have had fillers or botulinum toxin in the treatment area in the past 12 months
  • Subjects who have had treatments with poly-L-lactic acid in the face at any time
  • Subjects who have had any kind of facial dermabrasion, chemical peel, laser, or IPL treatment including superficial treatments for aesthetic reasons in the past 6 months or for the duration of the study
  • Subjects who does not agree to avoid using tanning beds or intensive exposure to the sun 2 two weeks prior to each office visit.
  • Subjects who have any dermatologic conditions including acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, infection or scars within the treatment area
  • Subjects who have an active inflammatory process (skin eruptions such as cysts, pimples, rashes or hives) or infection within the treatment area
  • Subjects who have any known cancer including skin cancers (basal cell carcinoma, squamous cell carcinoma and melanoma)
  • Subjects who have had systemic corticosteroid therapy in the past 6 months or for the duration of the study
  • Subjects with a known history of poor wound healing
  • Subjects with a known history of keloids (excessive scarring)
  • Subjects who are HIV positive
  • Subjects who have an existing medical condition that the Investigator considers may put the subject at risk or compromise their participation in the study
  • Subjects who have participated in another research study in the past 30 days
  • Subjects who are currently involved in any injury litigation claims

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02003833


Locations
Layout table for location information
United States, Indiana
Laser and Skin Surgery Center of Indiana
Carmel, Indiana, United States, 46032
United States, New York
Sadick Research Group
New York, New York, United States, 10075
Sponsors and Collaborators
Sadick Research Group
Investigators
Layout table for investigator information
Principal Investigator: Neil S Sadick, MD Sadick Research Group
Principal Investigator: William Hanke, MD Laser and Skin Surgery Center of Indiana
Additional Information:
Layout table for additonal information
Responsible Party: Neil Sadick, Medical Director, Sadick Research Group
ClinicalTrials.gov Identifier: NCT02003833    
Other Study ID Numbers: PLLA SkinQ
First Posted: December 6, 2013    Key Record Dates
Last Update Posted: November 20, 2015
Last Verified: November 2015
Keywords provided by Neil Sadick, Sadick Research Group:
Poly-L-lactic acid
Sculptra Aesthetic
Skin Quality
Wrinkles
Filler